{"id":531039,"date":"2021-02-20T18:26:02","date_gmt":"2021-02-20T18:26:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531039"},"modified":"2021-02-20T18:26:02","modified_gmt":"2021-02-20T18:26:02","slug":"trastuzumab-biosimilar-landscape-report-2020-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/trastuzumab-biosimilar-landscape-report-2020-by-delveinsight_531039.html","title":{"rendered":"Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1613625028.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1613625028.jpeg\" alt=\"Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cTrastuzumab\u2013 Biosimilar Insight, 2020,\u201d report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. <\/div>\n<p style=\"text-align: justify;\">DelveInsight launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Trastuzumab Biosimilar Insights 2020<\/strong><\/a>.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Trastuzumab Biosimilar Insight, 2020<\/strong><\/a>,&rdquo;&nbsp;report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in the Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/c3a3ef113a00d5475b894caeb184b750.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Trastuzumab Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medications. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/trastuzumab-biosimilars-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Click here and get access to free sample pages of the report.&nbsp;<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Trastuzumab Marketed drugs:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Kanjinti by Amgen<strong>&nbsp;<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Herzuma by Celltrion<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Trastuzumab Emerging drugs:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>EG12014 by EirGenix&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>HD201 by Prestige BioPharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The report covers detailed information of collaborations, acquisition, and merger, licensing along a thorough therapeutic assessment of emerging Trastuzumab biosimilar drugs.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a detailed sample copy of the report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/trastuzumab-biosimilars-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/trastuzumab-biosimilars-insight<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Trastuzumab Biosimilars: Snapshot<\/p>\n<p style=\"text-align: justify;\">3. Executive Summary<\/p>\n<p style=\"text-align: justify;\">4. Regulatory Outlook For Biosimilars<\/p>\n<p style=\"text-align: justify;\">5. Trastuzumab (Reference Product:&nbsp;Herceptin)<\/p>\n<p style=\"text-align: justify;\">6. Research and Development<\/p>\n<p style=\"text-align: justify;\">7. Herceptin Biosimilar:&nbsp;Emerging Opportunities<\/p>\n<p style=\"text-align: justify;\">8. Trastuzumab: Biosimilars Assessment<\/p>\n<p style=\"text-align: justify;\">9. Trastuzumab Biosimilars Profiles: By Company<\/p>\n<p style=\"text-align: justify;\">10. Trastuzumab Biosimilars: Comparative Landscape: By Company<\/p>\n<p style=\"text-align: justify;\">11. Trastuzumab Biosimilars: Competitive Landscape<\/p>\n<p style=\"text-align: justify;\">12. Market Drivers<\/p>\n<p style=\"text-align: justify;\">13. Market Barriers<\/p>\n<p style=\"text-align: justify;\">14. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">15. Appendix&nbsp;<\/p>\n<p style=\"text-align: justify;\">16. Bibliography<\/p>\n<p style=\"text-align: justify;\">17. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">18. Disclaimer<\/p>\n<p style=\"text-align: justify;\">19. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Download our full report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/><span>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><br \/><span><br \/><\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=trastuzumab-biosimilar-landscape-report-2020-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=trastuzumab-biosimilar-landscape-report-2020-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cTrastuzumab\u2013 Biosimilar Insight, 2020,\u201d report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/trastuzumab-biosimilar-landscape-report-2020-by-delveinsight_531039.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531039","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531039"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531039\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}